Celebrating 25 years Est 1999-2024
*Across 3 years $2276.64 only $796.82
Antisense Therapeutics Selected to Present at Biotech Showcase™ 2014 PR Newswire SAN FRANCISCO, Jan. 7, 2014 SAN FRANCISCO, Jan. 7, 2014...
Positive Results Achieved from Interim Analysis of ATL1103 Phase II Trial PR Newswire TOORAK, Australia, Dec. 23, 2013 TOORAK, Australia, Dec...
ANP to present at and attend major US investment, partnering and industry conferences PR Newswire TOORAK, Australia, Aug. 28, 2013 TOORAK...
Antisense Therapeutics Announces Launch of Level 1 American Depository Receipt Program Phase 2a Clinical Study for MS and Proof of Concept Study...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.